These efforts include evaluating antibodies against other immune checkpoints upregulated during immune exhaustion, such as a three-arm phase 2 trial (NCT05645692) of tobemstomig [a bispecific antibody against programmed cell death protein 1 (PD-1) and LAG-3] and tiragolumab (antibody against TIGIT) compared to tobemstomig alone or atezolizumab alone for patients with previously untreated aUC ineligible for PBC. The gene discussed is PDCD1; the disease is primary biliary cholangitis.